Summary
EudraCT Number: 2006-000608-18
Sponsor's Protocol Code Number: ML20243
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Ongoing
Date on which this record was first entered in the EudraCT database: 2006-04-04
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000608-18/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2006-000608-18
A.3 Full title of the trial: Estudio abierto y aleatorizado, comparativo de la tolerabilidad renal de Bondronat® 6 mg I.V. en perfusión de 15 minutos frente a 60 minutos en pacientes con metástasis óseas


A.3.2 Name or abbreviated title of the trial where available: Estudio BON15
A.4.1 Sponsor's protocol code number: ML20243
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Roche Farma, S.A.
B.1.3.4	Country: Spain
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: Bondronat 6 mg/6 ml concentrado para solución para perfusión
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Limited
D.2.1.2 Country which granted the Marketing Authorisation: Spain
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Bondronat 6 mg/6 ml concentrado para solución para perfusión
D.3.2 Product code: Ro 200-5450
D.3.4 Pharmaceutical form: Concentrate for solution for infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Ácido ibandrónico
D.3.9.2 Current sponsor code: Ro 200-5450
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 6mg/ 6ml 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Prevención de las complicaciones óseas en pacientes oncológicos que presentan metástasis óseas
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Classification code: 10049038
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: El objetivo principal de este estudio es demostrar la equivalencia entre Bondronat® 6 mg perfundido en 15 minutos y Bondronat® 6 mg perfundido en 60 minutos en cuanto a la tolerabilidad renal.
E.2.2 Secondary objectives of the trial: Los objetivos secundarios del ensayo consisten en comparar entre los dos grupos:
—	 La tolerabilidad
—	 La intensidad del dolor óseo
—	 El consumo de analgésicos 
—	 Las complicaciones óseas
—	 El índice del estado funcional de ECOG
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: 1.	Pacientes mayores de 18 años de edad 
2.	Pacientes que presenten neoplasias confirmadas citológica o histológicamente (los pacientes con cáncer de próstata deben haber manifestado progresión de su enfermedad a pesar de haber recibido como mínimo tres meses de terapia hormonal, entendiendo como progresión un incremento del PSA medido en tres ocasiones distintas con el menos dos semanas de diferencia o clara evidencia de nuevas metástasis óseas)
3.	Pacientes con al menos una metástasis ósea (osteoblástica, osteoclástica o mixta) documentada por gammagrafía, radiografía, TAC o RM.
4.	Pacientes que hayan firmado libremente su consentimiento informado por escrito
5.	Pacientes capaces de cumplir con los procedimientos del estudio
6.	En el caso de los pacientes mujeres en edad fértil:
-	prueba de embarzo (ß-HCG) negativa
-	método anticonceptivo eficaz
7.	Índice del estado funcional de ECOG ≤2
8.	Esperanza de vida ≥ 6 meses
9.	Aclaramiento de creatinina (calculado según la fórmula de Cockcroft y Gault) ≥ 30 ml/min 
E.4 Principal exclusion criteria: 1.	Pacientes mujeres que estén embarazadas o en periodo de lactancia
2.	Paciente con algún problema dentario en curso, en especial infección dentaria o maxilar; traumatismo o intervención quirúrgica dentaria o maxilar en las 6 semanas previas; antecedentes de osteonecrosis maxilar o de retraso de la cicatrización tras una intervención dentaria
3.	Metástasis cerebrales no controladas
4.	Infección severa o concomitante (neumonía, septicemia, pielonefritis, etc.)
5.	Antecedente conocido de enfermedad sistémica con afectación renal (lupus, enfermedad de Wegener, amiloidosis, etc.)
6.	Insuficiencia renal rápidamente progresiva en la inclusión
7.	Trastorno cardiaco no controlado (hipertensión arterial, arritmia, insuficiencia cardiaca congestiva, angina pectoris, etc.)
8.	Hipercalcemia (> 2,7 mmol/L), hipocalcemia (< 2 mmol/L) 
9.	Pacientes en tratamiento concomitante con quimioterapia nefrotóxica (metotrexato a dosis > 50 mg/m² o cisplatino) o que la hayan recibido en las 6 semanas previas a la randomización. 
10.	Pacientes elegibles para trasplante de células germinales hematopoyéticas en el momento de la inclusión
11.	Pacientes que hayan recibido un bifosfonato en las tres semanas previas a la aleatorización
12.	Hipersensibilidad conocida al ibandronato o a otro bifosfonato

E.5 End points
E.5.1 Primary end point(s): La variable principal del ensayo será la tolerabilidad renal, definida por el aclaramiento de creatinina (calculado según la fórmula de Cockcroft y Gault) 28 días después del fin del tratamiento.
Variables secundarias:
•	Tolerabilidad (acontecimientos adversos, acontecimientos adversos graves) hasta los 6 meses
•	Tolerabilidad renal (creatinina sérica, valor inverso de la creatinina sérica, aclaramiento calculado) cada 3 semanas hasta los 6 meses 
•	Eficacia sobre el dolor óseo, evaluada mediante una EAV (véase el Apéndice 5) cada 3 semanas durante 6 meses
•	Consumo de analgésicos según los 3 peldaños de la OMS 
•	Presentación de complicaciones óseas, evaluadas clínicamente o mediante los métodos de diagnóstico por imagen que el investigador considere adecuados (gammagrafía, radiografía, TAC, RM): fracturas vertebrales y no vertebrales, necesidad de radioterapia o de cirugía ósea, aparición de una nueva metástasis ósea
•	Índice del estado funcional de ECOG, evaluado cada 3 semanas durante 6 meses

E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: Information not present in EudraCT
E.6.2 Prophylaxis: Information not present in EudraCT
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Information not present in EudraCT
E.6.7 Pharmacodynamic: Information not present in EudraCT
E.6.8 Bioequivalence: Information not present in EudraCT
E.6.9 Dose response: Information not present in EudraCT
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: Information not present in EudraCT
E.6.12 Pharmacoeconomic: Information not present in EudraCT
E.6.13 Others: Information not present in EudraCT
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: No
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: Ácido ibandrónico (Bondronat®) 6 mg en 60 minutos
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: El final del tratamiento esta definido como la fecha de la última visita del último paciente, sin embargo, las excepciones deben justificarse.
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 7
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2006-04-04) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 206
F.4.2 For a multinational trial

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2006-05-24
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2006-05-11

P. End of Trial
P. End of Trial Status: Ongoing

